» Articles » PMID: 17721373

Admission Clinical and Laboratory Factors Associated with Death in Children with Cancer During a Febrile Neutropenic Episode

Abstract

Background: Early identification of children with cancer at risk for death during a febrile neutropenic (FN) episode may increase their possibility for survival. Our aim was to identify at the time of admission, clinical and laboratory variables differing significantly among children who survived or died during a FN episode.

Methods: In a prospective, multicenter study, children admitted with a high-risk FN episode were uniformly evaluated at enrollment and managed according to a national consensus protocol. Medical charts of children who died were evaluated to determine whether the death could be associated with an infection. Admission clinical and laboratory variables significantly associated with death were identified.

Results: A total of 393 (70%) of 561 FN episodes evaluated from June 2004 to December 2005 were classified as high risk for invasive bacterial infection, of which 14 (3.6%) resulted in an infectious-related death. Deaths occurred from 2 to 27 days after admission, and most dying children were admitted with relapse of acute lymphocytic leukemia (36%), hypotension (71%), and a diagnosis of sepsis (79%), compared with surviving children (16%, 20%, and 5% respectively, P < 0.001). Children who died were admitted with lower absolute neutrophil count (P < 0.001) and absolute monocytes count levels (P = 0.008), higher blood urinary nitrogen (P = 0.03) and C-reactive protein values (P < 0.001), and had more positive cultures (79% versus 32%, P = 0.008).

Conclusions: We identified early clinical and laboratory findings significantly associated with death occurring at a later stage. Routine evaluation of these variables may prove to be useful in the early identification of children with a high-risk FN episode at risk for death.

Citing Articles

Cathelicidin, but not vitamin D, is associated independently with sepsis in pediatric patients with cancer and febrile neutropenia.

Garcia-Garcia P, Palomo-Colli M, Silva-Jivaja K, Juarez-Villegas L, Vidal-Romero G, Sanchez-Rodriguez M Mol Clin Oncol. 2025; 22(2):22.

PMID: 39776942 PMC: 11706457. DOI: 10.3892/mco.2024.2817.


Warming up for a better fever: a randomized pilot study in pediatric oncology.

Krafft H, Raak C, Jenetzky E, Zuzak T, Langler A, Martin D Pilot Feasibility Stud. 2022; 8(1):183.

PMID: 35974359 PMC: 9380316. DOI: 10.1186/s40814-022-01144-7.


A prediction model for bacteremia and transfer to intensive care in pediatric and adolescent cancer patients with febrile neutropenia.

Alali M, Mayampurath A, Dai Y, Bartlett A Sci Rep. 2022; 12(1):7429.

PMID: 35523855 PMC: 9076887. DOI: 10.1038/s41598-022-11576-z.


The Pattern of Microorganisms and Drug Susceptibility in Pediatric Oncologic Patients with Febrile Neutropenia.

Jungrungrueng T, Anugulruengkitt S, Lauhasurayotin S, Chiengthong K, Poparn H, Sosothikul D J Pathog. 2021; 2021:6692827.

PMID: 33854800 PMC: 8021465. DOI: 10.1155/2021/6692827.


Role of urine studies in asymptomatic febrile neutropenic patients presenting to the emergency department.

Zgheib H, El Zakhem A, Wakil C, Cheaito M, Cheaito R, Finianos A World J Emerg Med. 2021; 12(2):99-104.

PMID: 33728001 PMC: 7947557. DOI: 10.5847/wjem.j.1920-8642.2021.02.003.